<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">IRBESARTAN</span><br/>(ir-be-sar'tan)<br/><span class="topboxtradename">Avapro<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">angiotensin ii receptor antagonist</span><br/><b>Prototype: </b>Losartan<br/><b>Pregnancy Category: </b>C (first trimester); D (second and third trimesters)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>75 mg, 150 mg, 300 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Irbesartan is an angiotensin II receptor (type AT<sub>1</sub>) antagonist. Angiotensin II is a hormone of the reninangiotensinaldosterone system. Irbesartan selectively blocks
         the binding of angiotensin II to the AT<sub>1</sub> receptors found in many tissues (e.g., vascular smooth muscle, adrenal glands).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Binding to the receptors results in blocking the vasoconstricting and aldosterone-secreting effects of angiotensin II, thus
         resulting in an antihypertensive effect.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Hypertension, treatment of diabetic nephropathy in patients with hypertension and type 2 diabetes.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>CHF.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to irbesartan, losartan, or valsartan; pregnancy [(category C first trimester), category D (second and third
         trimesters)], lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients on diuretics, arterial stenosis of the renal artery, severe CHF.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 150 mg once daily, may increase to 300 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Correct volume depletion prior to initiation of therapy to prevent hypotension. Titrate daily dose up to 300 mg; larger doses,
            however, are not likely to provide additional benefit.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Edema, fatigue, pain. <span class="typehead">CNS:</span> Dizziness, headache, anxiety, nervousness. <span class="typehead">CV:</span> Tachycardia, chest pain. <span class="typehead">GI:</span> Diarrhea, dyspepsia, nausea, vomiting, abdominal pain. <span class="typehead">Respiratory:</span> Upper respiratory infection, cough, sinus disorder, pharyngitis, rhinitis. <span class="typehead">Skin:</span> Rash. <span class="typehead">Other:</span> UTI. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract, 6080% bioavailability. <span class="typehead">Distribution:</span> 90% protein bound. <span class="typehead">Metabolism:</span> Metabolized in the liver primarily by CYP2C9. <span class="typehead">Elimination:</span> Primarily excreted in feces (80%). <span class="typehead">Half-Life:</span> 1115 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness: Maximum pressure lowering effect may not be evident for 612 wk; indicated by
            decreases in systolic and diastolic BP.
         </li>
<li>Monitor BP periodically; trough readings, just prior to the next scheduled dose, should be made when possible.</li>
<li>Lab tests: Monitor periodically BUN and creatinine, serum potassium, and CBC with differential.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Inform physician immediately if you become pregnant.</li>
<li>Notify physician of episodes of dizziness, especially when making position changes.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>